Results 51 to 60 of about 166,627 (157)

From Mycosynthesis to Immunomodulation: Exploring the Safety, Adjuvant Potential and Microbiota Impact of Biogenic Silver Nanoparticles

Microbial Biotechnology, Volume 19, Issue 7, July 2026.
Mycosynthesized silver nanoparticles from fungal strains act as safe, biocompatible vaccine adjuvants. They enhance immune responses in mice, promoting strong, dose‐dependent IgG2a polarization with minimal toxicity and limited gut microbiota disruption, highlighting their potential as versatile next‐generation platforms for subunit vaccine development.
Ana Clara Muniz‐Lagos, Diego M. Roldán, Paula Arbildi, Gustavo Mourglia‐Ettlin, Silvana Alborés   +4 more
wiley   +1 more source

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: results from a dose-finding clinical trial in older adults

, 2012
Background: MF59-adjuvanted influenza vaccines have superior immunogenicity in older adults compared with non-adjuvanted vaccines. We assessed whether changing formulation (i.e., increasing H3N2 antigen or decreasing the quantity of adjuvant) of the ...
Nicolay, Uwe, Del Giudice, Giuseppe, Groth, Nicola, Leroux-Roels, Geert, Galli, Grazia, Della Cioppa, Giovanni, Clement, Frédéric, Castellino, Flora, Lindert, Kelly   +8 more
core   +1 more source

Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin. [PDF]

, 2009
BACKGROUND: An association was previously established between facial nerve paralysis (Bell's palsy) and intranasal administration of an inactivated influenza virosome vaccine containing an enzymatically active Escherichia coli Heat Labile Toxin (LT ...
Kromann Ingrid, Woodrow, M, Novicki Deborah, Huo, Z, Del Giudice Giuseppe, Novicki, D, Rappuoli Rino, Thierry-Carstensen, B, Susan Barnett, Galiza, E, David J M Lewis, Rafaela Giemza, Andersen, P, Peter Andersen, Lewis David J. M., Barnett Susan, Maria Woodrow, Kromann, I, Giuseppe Del Giudice, Thierry-Carstensen Birgit, Giemza Rafaela, Ingrid Kromann, Andersen Peter, Lewis, DJ, Galiza Eva, Giemza, R, Huo Zhiming, Woodrow Maria, Deborah Novicki, Eva Galiza, Birgit Thierry-Carstensen, Rino Rappuoli, Del Giudice, G, Rappuoli, R, Barnett, S, Zhiming Huo   +35 more
core   +1 more source

AS03- and MF59-Adjuvanted Influenza Vaccines in Children

Frontiers in Immunology, 2017
Influenza is a major cause of respiratory disease leading to hospitalization in young children. However, seasonal trivalent influenza vaccines (TIVs) have been shown to be ineffective and poorly immunogenic in this population.
Amanda L. Wilkins, Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran, Bali Pulendran, Bali Pulendran, Bali Pulendran, Claire-Anne Siegrist, Andrew J. Pollard   +9 more
doaj   +1 more source

Immunogenicity of a Multi‐Epitope Influenza Composite Peptide Vaccine Targeting Human, Swine, and Avian Viruses: Advancing Pandemic Preparedness

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background The emergence of novel reassortant influenza A virus strains and zoonotic transmission to the human population is a critical factor in the development of a global pandemic, as exemplified by the 2009 swine flu pandemic and the ongoing threat of an H5N1 avian flu pandemic.
Nimisha Rikhi, Clara J. Sei, Kellie A. Fraser, Kevin Muema, Aba Assiaw‐Dufu, Richard F. Schuman, Gerald W. Fischer   +6 more
wiley   +1 more source

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

, 2011
Oil-in-water emulsions have been successfully used to increase the efficacy, immunogenicity, and cross-protection of human vaccines; however, their mechanism of action is still largely unknown.
Annalisa Colaprico, Michele Pallaoro, Derek T. O'Hagan, Mariagrazia Pizza, Alessia Genovese, Laura Santini, Rino Rappuoli, Andreas Wack, Ennio De Gregorio, Susanna Aprea, Marzia M. Giuliani, Anja Seubert, Ugo D'Oro, Sara Valentini, Samuele Calabro, Barbara Galli   +15 more
core   +1 more source

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children

International Journal of Infectious Diseases, 2019
Objective: To demonstrate the potential of an MF59-adjuvanted inactivated trivalent seasonal influenza vaccine (aIIV3; Fluad™) to improve the immune response in young children, we review the immunogenicity, efficacy, and safety/tolerability of aIIV3 from
Sanjay S. Patel, Svetlana Bizjajeva, Kelly Lindert, Esther Heijnen, Janine Oberye   +4 more
doaj   +1 more source

A chemokine-fusion vaccine targeting immature dendritic cells elicits elevated antibody responses to malaria sporozoites in infant macaques

Scientific Reports, 2021
Infants and young children are the groups at greatest risk for severe disease resulting from Plasmodium falciparum infection. We previously demonstrated in mice that a protein vaccine composed of the chemokine macrophage inflammatory protein 3α ...
Kun Luo, James T. Gordy, Fidel Zavala, Richard B. Markham   +3 more
doaj   +1 more source

The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025

Transplant Infectious Disease, Volume 28, Issue 3, May/June 2026.
This review synthesizes discussions from the 2025 International CMV Symposium on translating three recently updated international guidelines into clinical practice across solid organ and hematopoietic stem cell transplantation, highlighting advances in risk‐stratified prevention, emerging therapies, immune monitoring, and persistent implementation ...
Camille N. Kotton, Martina Sester, Julian Torre‐Cisneros, The International CMV Symposium Faculty   +3 more
wiley   +1 more source

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications

, 2007
The immunogenicity and reactogenicity of two influenza vaccines were evaluated in a randomised, double-blind trial in north-east Italy during winter 2005-2006. Of 238 adult subjects (18-60 years of age) with underlying chronic diseases, 120 received MF59-
TRIVELLO, RENZO, A. M. Carraro, FLOREANI, ANNAROSA, BALDO, VINCENZO, BALDOVIN, TATJANA, Family Medicine Group of Pianiga   +5 more
core   +1 more source